BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Risitano AM, Marotta S. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. Am J Hematol 2018;93:564-77. [PMID: 29314145 DOI: 10.1002/ajh.25016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Jager NM, van Zanden JE, Subías M, Leuvenink HGD, Daha MR, Rodríguez de Córdoba S, Poppelaars F, Seelen MA. Blocking Complement Factor B Activation Reduces Renal Injury and Inflammation in a Rat Brain Death Model. Front Immunol 2019;10:2528. [PMID: 31736957 DOI: 10.3389/fimmu.2019.02528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
3 Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol 2021;8:e344-54. [PMID: 33765419 DOI: 10.1016/S2352-3026(21)00028-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Notaro R, Sica M. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications. Semin Hematol 2018;55:130-5. [PMID: 30032749 DOI: 10.1053/j.seminhematol.2018.05.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
5 Gullipalli D, Zhang F, Sato S, Ueda Y, Kimura Y, Golla M, Miwa T, Wang J, Song WC. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis. J Immunol 2018;201:1021-9. [PMID: 29898960 DOI: 10.4049/jimmunol.1800384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
7 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020;220:108598. [PMID: 32961333 DOI: 10.1016/j.clim.2020.108598] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 34.0] [Reference Citation Analysis]
9 Harder MJ, Höchsmann B, Dopler A, Anliker M, Weinstock C, Skerra A, Simmet T, Schrezenmeier H, Schmidt CQ. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Front Immunol 2019;10:1639. [PMID: 31379839 DOI: 10.3389/fimmu.2019.01639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
10 Ito K, Angata K, Kuno A, Okumura A, Sakamoto K, Inoue R, Morita N, Watashi K, Wakita T, Tanaka Y, Sugiyama M, Mizokami M, Yoneda M, Narimatsu H. Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus. Hepatol Res 2020;50:1128-40. [PMID: 32738016 DOI: 10.1111/hepr.13552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol 2018;14:857-72. [PMID: 30204521 DOI: 10.1080/1744666X.2018.1521722] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
12 Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol 2018;55:167-75. [PMID: 30032754 DOI: 10.1053/j.seminhematol.2018.02.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
13 Becktell K, Berlyne D, Pagliuca S, Pommert L, Prata PH, Margolis D, de Latour RP, Dufour C, Pierri F. Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018. Leuk Res 2019;80:19-25. [PMID: 30908982 DOI: 10.1016/j.leukres.2019.03.003] [Reference Citation Analysis]
14 Fattizzo B, Serpenti F, Giannotta JA, Barcellini W. Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. J Clin Med 2021;10:948. [PMID: 33804461 DOI: 10.3390/jcm10050948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D’adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018;132:547-50. [DOI: 10.1182/blood-2018-03-835413] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
16 Dobó J, Kocsis A, Gál P. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases. Front Immunol 2018;9:1851. [PMID: 30135690 DOI: 10.3389/fimmu.2018.01851] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
17 Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Sultan EY, Rizk DE, Kenawy HI, Hassan R. A small fragment of factor B as a potential inhibitor of complement alternative pathway activity. Immunobiology 2021;226:152106. [PMID: 34147816 DOI: 10.1016/j.imbio.2021.152106] [Reference Citation Analysis]
19 Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. J Med Chem 2018;61:6153-62. [PMID: 29920096 DOI: 10.1021/acs.jmedchem.8b00560] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
20 Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv 2019;3:3575-8. [PMID: 31738828 DOI: 10.1182/bloodadvances.2019000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 de Latour RP, Risitano A, Dufour C. Severe Aplastic Anemia and PNH. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 579-85. [DOI: 10.1007/978-3-030-02278-5_77] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
23 Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q, Xiao H, Springer C, Ehrlich G, Kamat V, Rafique A, Hu Y, Krueger P, Huang T, Poueymirou W, Babb R, Rosconi MP, Retter MW, Chen G, Morton L, Zambrowicz B, Cao J, Romano C, Olson WC. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One 2020;15:e0231892. [PMID: 32384086 DOI: 10.1371/journal.pone.0231892] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
24 Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A 2019;116:7926-31. [PMID: 30926668 DOI: 10.1073/pnas.1820892116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
25 Bozio CH, Isenhour C, McNamara LA. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS One 2020;15:e0241989. [PMID: 33180804 DOI: 10.1371/journal.pone.0241989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Jodele S. Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies. Semin Hematol 2018;55:159-66. [PMID: 30032753 DOI: 10.1053/j.seminhematol.2018.04.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
27 Mannes M, Dopler A, Zolk O, Lang SJ, Halbgebauer R, Höchsmann B, Skerra A, Braun CK, Huber-Lang M, Schrezenmeier H, Schmidt CQ. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood 2021;137:443-55. [PMID: 33507296 DOI: 10.1182/blood.2020005959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
28 Risitano AM, Peffault de Latour R. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol 2021. [PMID: 34355382 DOI: 10.1111/bjh.17753] [Reference Citation Analysis]
29 Fattizzo B, Kulasekararaj AG. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. BioDrugs 2020;34:149-58. [PMID: 31916226 DOI: 10.1007/s40259-019-00401-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
30 Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol 2019;10:1157. [PMID: 31258525 DOI: 10.3389/fimmu.2019.01157] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]